The finding that niraparib decreased replication fork restart (Fig. 2a) and increased genomic instability (Fig. 2c, d) is consistent with the molecular mechanism of synthetic lethality in PARP1 inhibition in BRCA1 and 2-deficient breast and ovarian cancers [12, 13, 18]. Here, PARP1 is linked to ovarian carcinoma.